ストックスクリーナーアプリを入手
91.48
0.09%
-0.08
前日終値:
$91.56
開ける：
$91.38
24時間の取引高:
1.13M
Relative Volume:
1.19
時価総額：
$23.13B
収益：
$3.26B
当期純損益:
$-1.45B
株価収益率:
-15.58
EPS:
-5.871
ネットキャッシュフロー:
$1.18B
1週間 パフォーマンス:
-0.01%
1か月 パフォーマンス:
-0.80%
6か月 パフォーマンス:
-16.07%
1年 パフォーマンス:
-17.62%
1日の値動き範囲:
$90.96
$92.10
1週間の範囲:
$88.35
$92.76
52週間の値動き範囲:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
91.48 | 23.15B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-02 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | アップグレード | Goldman | Neutral → Buy |
| 2025-06-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-05-29 | 開始されました | Goldman | Neutral |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-01-10 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2024-11-19 | 開始されました | Berenberg | Buy |
| 2024-11-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-11-08 | アップグレード | Goldman | Neutral → Buy |
| 2024-09-24 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-09-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-08-07 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-08-02 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-14 | 開始されました | Evercore ISI | In-line |
| 2024-02-23 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-05 | 開始されました | Oppenheimer | Perform |
| 2023-12-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-10-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-17 | アップグレード | Redburn | Neutral → Buy |
| 2022-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-08-17 | 開始されました | Cowen | Market Perform |
| 2022-07-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2021-12-16 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-08-11 | アップグレード | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-16 | ダウングレード | Redburn | Neutral → Sell |
| 2021-05-18 | 開始されました | Goldman | Neutral |
| 2021-05-11 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-08-03 | 再開されました | Berenberg | Buy |
| 2020-07-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-06-30 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 開始されました | H.C. Wainwright | Neutral |
| 2020-01-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-11-05 | 開始されました | Wolfe Research | Outperform |
| 2019-11-04 | 開始されました | Berenberg | Buy |
| 2019-11-04 | 開始されました | BofA/Merrill | Buy |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-11-04 | 開始されました | JP Morgan | Overweight |
| 2019-11-04 | 開始されました | SVB Leerink | Outperform |
| 2019-11-04 | 開始されました | UBS | Buy |
すべてを表示
Biontech Se Adr (BNTX) 最新ニュース
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
BioNTech's Balancing Act: Plant Closures, Founders' Exit, and a Bet on Six Key Cancer Studies - aktiencheck.de
BioNTech’s Triple Transformation: Shuttering Plants, Losing Founders, and Banking on 15 Cancer Trials - aktiencheck.de
SK Hynix readies U.S. market debut as NATO strains and Gulf shipping risks unsettle investors - Traders Union
Cathie Wood Scoops Up SpaceX Shares Again as Stock Dips, Ark Keeps Offloading AMD Shares - Sahm
Cathie Wood’s ARK sells BioNTech and buys SpaceX stock - Investing.com
10 Newly Overvalued Stocks this Week - Morningstar
BioNTech’s Factory Sell-Off and a Founder’s Spin-Off: Two Bets That Could Reshape the Stock - aktiencheck.de
PTC Therapeutics (PTCT) moves 7.2% higher: Will this strength last? - MSN
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week? - TradingView
European ADRs Jumped As Biotech Led The Pack - Finimize
BioNTech SE ADR (BNTX) News Today: Latest Market and Industry Updates - Traders Union
BioNTech stock trades down as founders leave the company, raising transition concerns - Traders Union
Comirnaty Omicron-adapted formulation from BioNTech SEupdated mRNA shot for the 2024-25 season - ad-hoc-news.de
Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech SE Sponsored ADR Actuals & Estimates (NASDAQ:BNTX) - TradingView
Price to sales forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
Enterprise value to EBIT forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech’s Oncology Transformation Hinges on Dense Second-Half Data Flow () - aktiencheck.de
BioNTech (BNTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Price to earnings forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
Ubiquiti Upgraded, Reddit Downgraded: Updated Rankings on Top Blue-Chip Stocks - Yahoo Finance
BioNTech's €16.8 Billion Cash Hoard Is the Prize as Moderna Circles Factories and Spin-Off Looms - aktiencheck.de
Why BioNTech’s BNT316/ ONC-392 could quietly change lung cancer care - Ad-hoc-news.de
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance
BioNTech Faces Shareholder Revolt Over Spin-Off Even as It Prepares First US Cancer Filing - aktiencheck.de
BioNTech Slashes 1,800 Jobs and Kicks Off $1 Billion Buyback in Oncology Push () - aktiencheck.de
BioNTech SE Stock (US09075V1026): Buyback And Oncology Pipeline Keep Shares In Focus - Ad-hoc-news.de
BioNTech Stands at a Pivotal Juncture as First FDA Filing Approaches and Pipeline Data Piles Up - aktiencheck.de
Moderna Says New COVID Vax Doesn't Infringe BioNTech IP - Law360
BioNTech's $1 Billion Buyback Marches Forward as Founders Exit and Cancer Trials Intensify - aktiencheck.de
BioNTech Has $16.8 Billion in Cash, a $1 Billion Buyback, and Promising Cancer Data — So Why Is the Stock Stuck? - aktiencheck.de
BioNTech: When Pipeline Progress Meets a Market That Demands Revenue () - aktiencheck.de
Comirnaty COVID-19 Vaccine: What Matters Now for US Patients - AD HOC NEWS
Bristol-Myers Upgraded, Broadcom Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech’s Pipeline Pivot Meets a Market That Won’t Look Up () - aktiencheck.de
BioNTech Stock: A Week of Crosscurrents Where Macro and a Medical Congress Collide () - aktiencheck.de
BioNTech Faces Twin Headwinds: Analyst Divergence and German Health Overhaul () - aktiencheck.de
Bernstein reiterates BioNTech stock rating on pumitamig risks - Investing.com
BioNTech's Oncology Momentum Clashes With Berlin's Health-Cost Crackdown () - aktiencheck.de
BioNTech’s Costly Pivot: Cancer Pipeline Promises Meet Political and Financial Realities () - aktiencheck.de
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
BioNTech's ASCO Data Showcase Two Late-Stage Hopes Amid Cost Cuts and a $1 Billion Buyback - aktiencheck.de
BNTX Technical Analysis | Trend, Signals & Chart Patterns | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech Races Toward First Oncology Approval as ASCO Data Bolsters Pipeline Credibility - aktiencheck.de
BNTX Stock Quote Price and Forecast - CNN
Pumitamig’s 72.7% Response at Reduced Dose Reshapes BioNTech’s Oncology Ambitions () - aktiencheck.de
BioNTech’s ASCO Data Blitz Fails to Close Analyst Split as First FDA Filing Looms () - aktiencheck.de
BioNTech Juggles Vaccine Tweaks and Cancer Milestones as Investors Look Beyond COVID - aktiencheck.de
BioNTech Shows Its Hand at ASCO: A Pipeline in Full Bloom and a Radical Cost Overhaul () - aktiencheck.de
BNTXBioNTech SE ADR Dividends - Finviz
Biontech Se Adr (BNTX) 財務データ
収益
当期純利益
現金流量
EPS
Biontech Se Adr (BNTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Poetting Sierk | Chief Operating Officer |
Apr 22 '26 |
Sale |
110.56 |
50,000 |
5,527,960 |
399,387 |
0.80%
2.11%
大文字化:
|
ボリューム (24 時間):